Skip to main content
Figure 1 | Alzheimer's Research & Therapy

Figure 1

From: Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias

Figure 1

Development timeline of Alzheimer's Drug Discovery Foundation-funded therapeutic strategies for Alzheimer's disease and related dementias. Each program presented at the 12th International conference on Alzheimer's Drug Discovery is highlighted in terms of position in the drug development lifecycle at the time of the meeting. *Allon Theraputics is currently in phase II/III for progressive supranuclear palsy, following limited efficacy in a phase II trial of davunetide for Alzheimer's disease. NB: the purpose of this figure is to highlight the stage of development for each program that has benefited from Alzheimer's Drug Discovery Foundation funding, and is not indicative of Alzheimer's Drug Discovery Foundation funding throughout the entire program lifecycle. Multiple funders have contributed to many of these programs. Aβ, amyloid-β; ADME, absorption, distribution, metabolism and excretion; ADNF, activity dependent neurotrophic factor; AMPK, AMP activated protein kinase; APOE, apolipoprotein E; BACE, β-site APP cleaving enzyme; FTLD, frontotemporal lobar degeneration; HDAC, histone deacetylase; HSP, heat shock protein; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; MSKCC, Memorial Sloan Kettering Cancer Center; PDI, protein disulphide isomerase; PoC, proof of concept; RyR, ryanodine receptor; TfR, transferrin receptor; TMP, tetramethylpyrazine; TOMA, tau oligomer monoclonal antibody; TOX, toxicity; VILIP, Visinin-like protein.

Back to article page